Eu Cpnp Cosmetics Notification Consultant

Scope and evidence must be confirmed before any paid tests or filings.

An EU CPNP cosmetics notification consultant should first answer whether the product belongs in the cosmetics regime, who will be its EU responsible person (RP), and whether the supporting dossier is fit for the planned product and claims. Filing the portal form is a later execution task—not the classification or safety decision.

Under Regulation (EC) No 1223/2009, an applicable cosmetic must be notified through CPNP before being placed on the EU market. The Commission operates the portal free of charge; notification is not an approval, safety certificate or regulatory classification decision. One CPNP notification removes the need for further national cosmetic-product notification within the EU, but does not remove applicable labelling and other obligations.

First gate: is CPNP the correct route?

Article 2(1)(a) defines cosmetics by intended contact with specified external body parts, teeth or oral mucosa, and by a mainly cosmetic purpose (cleaning, perfuming, changing appearance, protecting, keeping in good condition or correcting odours). A product name, manufacturer’s certificate or foreign registration does not decide this. Check the full presentation, instructions, ingredients, intended users and advertising claims together.

Ordinary skin care, shampoo or perfume with cosmetic claims: usually assess under the Cosmetics Regulation, then examine the actual formula.
A product promoted as treating disease, disinfecting or achieving a medical function: stop and assess the medicinal, biocidal or medical-device boundary as applicable; do not assume CPNP is a substitute.
A borderline product: document the reasons for classification and any unresolved facts. Commission borderline materials are guidance, not a binding approval; national authorities and courts assess individual cases.

Route matrix: who is responsible for which notification?

The RP is not necessarily the brand owner or the consultant entering data. Article 4 determines the legal role, while Article 13 distinguishes RP submissions from a narrow distributor-translation scenario. Decide this before signing a filing mandate or printing an address.

Commercial arrangement	Decisive legal issue	Advisory decision
EU-established manufacturer of a cosmetic made in the EU, not subsequently exported and re-imported, marketing its own product	Is it the manufacturer under Article 4(3), or is there an accepted written RP mandate?	Confirm RP, product identity and PIF location; then plan Article 13 notification.
Non-EU-established manufacturer whose cosmetic is made in the EU and not exported then re-imported	Article 4(4): the non-EU manufacturer must appoint an EU-established RP by written mandate accepted in writing. This is not automatically an importer case.	Verify place of manufacture, cross-border movements and the accepted RP designation before deciding the filing actor.
Non-EU brand shipping finished cosmetics to an EU importer	Each importer is RP for the cosmetic it places on the market unless it has designated an EU-established RP by an accepted written mandate.	Map every importer and written mandate; do not treat the non-EU brand or a consultant login as the legal RP.
Distributor placing a cosmetic on the market under its own name/mark, or modifying it in a way that may affect compliance	Article 4(6) makes the distributor the RP if either condition is met; translation of product information alone is not that modification.	Reassess role, evidence control and notification rather than copying the supplier’s CPNP reference.
Distributor only translating labelling for another Member State on its own initiative	Translation alone does not make it RP, but Article 13(3) can require a limited distributor notification.	Distinguish the distributor route from a fresh RP product notification; verify the translation and facts.

The special Article 13(3) distributor notice applies only where a product has already been placed on the market in one Member State, the distributor makes it available in another, and independently translates label elements to comply with the latter State’s law. Translation by itself does not automatically require that notice.

Pre-filing gap register: distinguish blockers from fixable data

Ask for a version-controlled evidence pack. Classify every finding as STOP (legal route or responsible party unresolved), ASSESS (safety/ingredient evidence needs qualified review), or FIX (information or artwork needs correction). These are project triage labels, not official CPNP statuses.

Decision gate	Minimum material to inspect	Result if missing or inconsistent
Regulatory identity	Product use, complete claims and artwork, ingredient/function description, distribution plan.	STOP: decide cosmetics vs another regime before commissioning routine CPNP work.
RP / supply chain	EU manufacturer or importer entities, brands, accepted mandates, existing notification ownership.	STOP: resolve Article 4 responsibility and access to the technical file.
Formula and safety	Full quantitative composition, raw-material specifications, exposure/use information, relevant studies, qualified assessor’s EU CPSR and PIF evidence.	ASSESS: check Annex restrictions and evidence sufficiency; a foreign safety sheet alone is not an EU CPSR.
Notification identity	Product category/name(s), origin where imported, label and packaging images, contact details, poison-centre formulation information, variants and potential nanomaterials.	FIX or ESCALATE: align the dossier and CPNP data; for nanomaterials evaluate the separate Article 16 route.

Timing distinction: the RP’s core Article 13(1) information is notified before placing the product on the market; under Article 13(2), the original label and, where reasonably legible, packaging photograph are notified when it is placed on the market. Draft artwork can still be reviewed earlier for consistency.

Which existing evidence can actually be reused?

Reuse is an evidential judgment, not document translation. Article 10 requires a safety assessment by a suitably qualified assessor; Article 11 governs the Product Information File (PIF). An existing foreign or supplier file can be an input, but cannot be presumed sufficient for EU market access.

Usually reusable as inputs, subject to authenticity and product-version match: quantitative recipe, raw-material specifications, stability or microbiological evidence and packaging data.
Requires EU-specific validation: ingredient restrictions and concentration limits, claims support, warnings/language, exposure assumptions, assessor qualifications and CPSR/PIF completeness.
Do not automatically carry over: a third-country approval, another brand’s CPNP reference, or a report covering a different formula, shade, fragrance, use or packaging exposure. Decide variant scope by real differences, not SKU counts alone.

A decision-first sequence before testing or submission

Commission only the work needed for the selected legal route. CPNP does not prescribe one universal laboratory test menu; the assessor determines which reliable evidence is needed for the particular product. A practical sequence is:

Freeze intended use, actual advertising claims, sales territories and product/variant versions; resolve borderlines.
Identify the EU RP and obtain accepted mandates or verify importer/manufacturer status; establish who controls the dossier.
Screen quantitative formula and packaging against current requirements; flag restricted substances, nanomaterials and claims requiring evidence.
Ask the qualified safety assessor to specify the missing evidence, complete the CPSR/PIF review, then finalise compliant labels.
Only then prepare the RP’s Article 13 portal data (and an Article 16 route if applicable); record versions, handover and monitoring responsibilities.

Change-control triggers after the initial strategy

Treat the file and CPNP record as controlled information, not a one-time badge. Article 13(7) calls for updates to notified information without delay when it changes. The table indicates what to reassess; it does not imply that every change always needs a brand-new notification.

Trigger	Reassessment before deciding on an update
Formula, fragrance, colourant or raw-material supplier change	Recheck restrictions, safety/exposure, CPSR/PIF and whether the notified formula data or variant grouping changes.
New brand name, claims, target use or packaging	Check cosmetic classification, evidence for claims, product identity, label and safety assumptions.
New importer, RP or distribution structure	Check Article 4 mandate and obligations, PIF control, label address and the CPNP record/access strategy.
Translation for another EU market, or nanomaterial finding	Check applicable national label language and the Article 13(3) distributor case; separately screen Article 16 applicability.

Where consultancy ends and execution begins

The consultant’s useful deliverable is a reasoned classification note, an RP/market-route decision, a red-amber-green evidence gap register, a reuse-versus-retest recommendation and a versioned action plan. Actual CPNP notification submission, appointment and ongoing duties of an EU responsible person, and production/review of a CPSR and PIF are distinct workstreams. Engaging an adviser alone does not transfer statutory RP responsibility.

Questions that change the filing strategy

Our US or UK supplier already registered the formula locally. Can we submit it straight to CPNP?

No automatic equivalence applies. Check whether the marketed product is a cosmetic under EU law, identify its EU RP, validate ingredient restrictions and the EU CPSR/PIF, and then plan notification.

We have two EU importers for one brand. Who notifies?

Start with Article 4(5): each importer is RP for the product it places on the EU market unless an EU-established RP has been designated by accepted written mandate. Map which importer places which product and who controls the PIF before deciding the notification arrangement.

Can we use the previous brand owner’s CPNP reference after private-labelling?

Not as proof of your own compliance. Own-brand placement can change the RP under Article 4(6). Compare legal roles, formula/product identity, PIF access and portal records; then decide the appropriate notification/change route.

Will a successful CPNP submission certify safety or authorise marketing?

No. CPNP is a notification system, not approval. Safety assessment, PIF, compliant composition, claims and labelling remain separate obligations.

Does translation of an existing EU cosmetic label always require a new RP notification?

No. Article 4(6) says translation alone is not the relevant product modification. Under the specific facts in Article 13(3), a distributor translating labelling on its own initiative for another Member State must make a separate limited notification.

If the formula has a nanomaterial, is ordinary CPNP notification enough?

Not always. Identify the material and its regulatory function: some nanomaterials fall outside the additional Article 16(3) procedure, notably those covered by the Article 14 colourant, preservative or UV-filter rules. Where Article 16(3) applies, the separate notification is required six months before placing the product on the market, in addition to the ordinary Article 13 notification. Check the precise scope before setting the launch date. Also assess the Article 16(3) exception for products containing nanomaterials that comply with Annex III conditions.